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The importance of research involving human genetic or genomic 
information analysed together with other personal or health data 
for the understanding of multifactorial diseases has increased 
significantly over the past few decades. This type of research is 
vital for improvements in disease detection, prevention, diagnosis, 
intervention, treatment and cure, including the development of new 
products and services. It is therefore not surprising that growing 
prominence is being placed on the establishment and sharing of 
resources comprising data, human biological material (HBM) and 
information derived from their analysis.[1] This paper opens with a 
brief description of biobanks and then discusses some associated 
ethical and legal complexities in this context; it also attempts to 
stimulate debate on problems that may arise as a result of unforeseen 
biobank closure, a situation that has to date received very little 
attention in scholarly exploration. South Africa cannot afford to lag 
in this ‘new wave’ of research while several biobank initiatives are 
already underway, and one of the objects of this paper is to kindle 
deliberation on the subject.
What are biobanks?
Biobanks are repositories where organised collections of HBM and 
associated data from large numbers of individuals are collected, 
stored and distributed for the purpose of health research. Data 
include health, environment and lifestyle information, and often 
individuals are followed up over long periods. The repositories 
range from large national biobanks which cater for research into 
a range of conditions, to smaller units within institutions. The 
latter are used for research into a limited number of diseases or for 
disease-specific conditions.[2] Biobanks are further distinguished into 
being either public or private in nature. Public biobanks are often 
called population biobanks. HBM and associated data from public 
biobanks are used for the promotion of the health of the population.
[2] Hence, biobanks may be one of the following, or a combination 
thereof: cross-sectional, longitudinal, large-scale, disease-specific 
or population-based; and they provide platforms for international 
collaborations on a scale not previously achieved.[1] While the notion 
of biobanking is not new, the reliance on the use of biobanks 
involving an intersection of disciplines and generating knowledge 
across disciplines has increased significantly.[3] However, the open 
and evolving nature of biobanks has profound ethical, legal and social 
implications for individual and group autonomy, informed consent, 
privacy, confidentiality, secondary use of samples and data over time, 
return of results, data sharing, and benefit sharing with communities.
[3-5] There has been much discussion on these issues, but very little 
has been said about premature or unplanned closure which, in the 
context of biobanks, is fraught with challenges. In addition, another 
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layer of complexities emerge because of increasing international 
collaborations and differing national positions.
How does biobank research differ 
from conventional established 
research with biological specimens?[6]
Conventional research usually entails:
• one researcher or an already recognised set of researchers
• samples obtained and used in defined ways for research in 
discrete areas
• informed consent from each research participant for use of 
their sample, and permission to obtain, use and disclose the 
participants’ health information.
With biobank research:
• those obtaining the samples may be brokers or intermediaries 
who may supply specimens without necessarily being involved 
in the research
• the biobank sample repository can be used for many research 
projects and often in numerous scientific areas
• future research activities, including research by investigators 
who cannot be specified at the time of sample collection, are 
considered
• because several studies could use the biobank’s samples and 
data, a move from the classic research ethics paradigms on 
informed consent towards a format of broad or even blanket 
consent needs to be considered.
Risks of biobank research
While physical risks are rare, potential risks extend beyond the 
individual participant to population groups that the participant is 
associated with as well as the general public at large.[6] Common risks 
are usually social and dignitary. Social risks include stigmatisation 
and discrimination, are frequently group-based, and implicate both 
research participants and non-participants. Stigma and discrimination 
could arise when research findings indicate that members of certain 
sub-populations are more likely to have a genotype conferring an 
increased risk of disease or other traits. Genetic discrimination 
is widely feared. When identifiable samples are used in research, 
disclosure of sensitive information will result in an invasion of the 
participant donor’s privacy. Dignitary risks occur when religious or 
personal values are violated. Unidentifiable samples could lead to 
research that the donor may not approve of, e.g. use of samples for 
research on termination of pregnancy, to which the donor could have 
strong religious objections.[6] When analysing risks and benefits, it 
would be important to weigh the potential benefits of knowledge to 
be gained from the research against potential harm for participants 
and society at large.
Implications for informed consent
Informed consent is an ethical principle and a legal doctrine of shared 
decision making, and a central tenet of conventional traditional 
research. It allows individuals to exercise their fundamental right to 
decide whether and how their body, body parts and associated data 
will be used in research.[3] Classic research ethics focuses on individual 
consent which can only be obtained after the research has been 
approved by a research ethics committee (REC). Biobanks introduce 
a new paradigm that frequently separates the sample collection 
process (i.e. the informed consent process) from the actual research 
on the sample.[6] The research could be conducted many years later 
and may involve research questions and methods that could not 
have been contemplated at the time of sample collection. Samples 
are exchanged and data are distributed across complex databases. 
Samples may undergo transformation into specific cell lines that can 
themselves be duplicated and exchanged.[3] The supremacy of consent 
itself is challenged as it is ill-equipped to protect rights in the world 
of networks and extensive computerised processing of personal 
and health data over prolonged periods.[3] Use of informed consent 
language is also problematic. What is obtained is permission and not 
informed consent, as it is difficult for donors to make informed and 
voluntary choices throughout the life cycle of HBM in a biobank.[5]
To address the bottleneck between classic research ethics paradigms 
and the wider societal goals of biobank research, new guidelines and 
amendments to existing ones have proposed solutions to the informed 
consent impasse. Solutions include broad/blanket consent; multilayered 
consent with secondary use statements; recontact/reconsent 
mechanisms; presumed consent/opting out; and waived consent.[7] 
Biobank research entails a balanced choice between autonomy and 
the public good as the benefits of this type of research involve broader 
societal concerns of scientific advancements for diagnosis, prevention 
and treatment of disease, and increasing knowledge.
Property rights – some considerations
Property rights surrounding HBM, commoditisation of human tissue 
and medical data continue to be discussed at length, with competing 
values of fairness to donors and maintaining access to research 
materials dominating. Deep moral significance is attached to the 
donation of body parts, tissue and organs. Biobanks evoke the notion 
that property which is shared by all humanity must bear in mind 
population and individual considerations.
Current research ethics regulations are based on the principle 
of autonomy which is independent of any property right in one’s 
tissue.[1] Moreover, the traditional role of informed consent does not 
include that of soliciting and obtaining gifts of HBM. In exceptional 
situations, specimens can be so unique as to become the source of 
immortalised cell lines and other valuable products. Current case 
law demonstrates instances where disputes have arisen because 
researchers used samples without the necessary permission or when 
donors were exploited for financial and scientific gain.[8-10] It is difficult 
to apply traditional principles of delict, contract and property law to 
biobanks as knowledge generated by donated specimens and other 
information derived is not adequately categorised by property and 
contract dogma.[11]
Biobanks – ‘end of life’ issues
Biobank closure, sale, bankruptcy, end of funding and transfer 
of materials to other entities are issues that have not yet been 
explored adequately. Biobanks need to develop plans for appropriate 
transfer, disposition and destruction of HBM and data in the event 
of unexpected discontinuation, such as termination of funding, 
or if the bank no longer served a scientific or valuable purpose. 
Destroying specimens and samples under the control of the biobank 
is less complex than ensuring the destruction of resources that 
have been provided to third parties. While every effort could be 
made to retrieve and destroy all such specimens, data and samples, 
there may be circumstances where this is not feasible (e.g. if 
pooled samples are prepared or cell lines have been developed and 
disseminated anonymously). In addition, destroying all data may 
also be quite difficult as backup files may cover lengthy periods.[1] 
Different cultural and religious groups may have different attitudes to 
biological material, and these could change over time. Some cultural 
or religious groups may follow traditional practices in the disposal 
or destruction of HBM. While this will most probably be addressed 
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during the consent process, it will also be an important consideration 
at the point of disposal.[1]
Commercial biobanks, because they are a relatively new 
development, could be viewed as start-up ventures with the 
concomitant risk of business failure. Should a biobank company 
become bankrupt, the HBM and medical records may be its only 
substantial assets. Where a biobank files for bankruptcy, creditors 
would require that the sale and distribution of the assets are 
maximised – a situation that could be perceived as morally repugnant. 
Furthermore, there are complexities regarding the consent and 
confidentiality agreements obtained during donation and how these 
ethical values would now be protected. Currently, the trustee in the 
bankruptcy is legally in a position to breach any pre-existing contract 
to sell off assets. Legislation will have to be enacted to limit the ability 
of the biobank to accept donations only where the donor retains 
certain non-waivable property rights that would bind transferees 
of the information. Such a law would restrict the donor’s ability to 
make unconditional gifts, but there does not seem to be any other 
alternative.[6]
With increasingly long-term research, donor death in the context 
of biobanking must also be considered. Questions arise as to whether 
HBM and data should be returned to family members. In addition, 
consideration will have to be given to whether results from research 
should be provided to biological family members. Currently, most 
international guidelines have not considered the effect of donor death 
and the rights of persons enrolled in research who have already died. 
Neither is there any guidance on the rights of family members or 
the estate over the HBM, data and research results of the deceased 
donor. [12] It is recommended that these issues be discussed with the 
donor and be included in the informed consent process. The donor’s 
wishes in the event of death should be recorded and respected.
Public engagement and trust
The above issues make it clear that public consultation and involvement 
are very necessary to the success of biobanking. Public and community 
participation in research is not a new phenomenon. The public and 
even patient support groups are being increasingly recognised as 
active participants in the research process. Ongoing dialogue between 
the public, researchers and biobank managers is essential.[3]
Conclusion
A multitude of research questions remain unanswered. Much more 
transdisciplinary knowledge of genetic, environmental, psycho-
social and lifestyle factors that contribute to the development and 
progression of chronic diseases is necessary for advances in public 
health. Biobanks, with their HBM and databases, will play a critical 
role in answering these questions. While recognising the importance 
of pursuing scientific knowledge as essential to and in parallel 
with human progress, human wellbeing and the relief of suffering, 
it is vital that human dignity is respected and upheld. Currently, 
implementing national laws in an internationally consistent manner 
is problematic. National and international laws and policy guidelines 
will need to be amended or enacted to ensure that rights are protected 
in the world of networks and extensive computerised processing of 
personal and health data.
1. OECD Guidelines on Human Biobanks and Genetic Research Databases. Paris: OECD, 2009. http://
www.oecd.org/sti/biotechnologypolicies/44054609.pdf (accessed 22 November 2012).
2. O’Doherty KC, Hawkins AK, Burgess MM. Involving citizens in the ethics of biobank research: 
Informing institutional policy through structured public deliberation. Soc Sci Med 2012;75:1604-1611. 
[http://dx.doi.org/10.1016/j.socscimed.2012.06.026]
3. Cambon-Thomsen A, Rial-Sebbag E, Knoppers BM. Trends in ethical and legal frameworks for the use 
of human biobanks. Eur Respir J 2007;30(2):373-382.
4. Murphy J, Scott J, Kaufman D, Geller G, LeRoy L, Hudson K. Public perspectives on informed 
consent for biobanking. Am J Public Health 2009;99(12):2128-2134. [http://dx.doi.org/10.2105/
AJPH.2008.157099]
5. Winickoff DE, Winickoff RN. The charitable trust as a model for genomic biobanks. N Engl J Med 
2003;349:1180-1184. [http://dx.doi.org/10.1056/NEJMsb030036]
6. Rothstein MA. Expanding the ethical analysis of biobanks. J Law Med Ethics 2005;33(1):89-101. 
[http://dx.doi.org/10.1111/j.1748-720X.2005.tb00213.x]
7. Tasse AM, Budin-Ljosne I, Knoppers BM, Harris JR. Retrospective access to data: the ENGAGE 
consent experience. Eur J Hum Genet 2010;18:741-745. [http://dx.doi.org/10.1038/ejhg.2010.30]
8. Moore v. Regents of the Univ. Of Cali., 793 P.2d 479. Cal 1990.
9. Greenberg v. Miami Children’s Hospital, 264 F.Supp.2d 1064. S.D. Fla. 2003.
10. Dalton R. When two tribes go to war. Nature 2004;430(6999):500-502.
11. Palmer LL. Should liability play a role in the social control of biobanks? Journal of Law, Medicine and 
Ethics. 2005; 3: 70-78. [http://dx.doi.org/10.1111/j.1748-720X.2005.tb00211.x]
12. Knoppers BM, Hudson TJ. The art and science of biobanking. Hum Genet 2011;130(3):329-332. 
[http://dx.doi.org/10.1007/s00439-011-1067-9]
